# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094231
Filing Date
2024-08-09
Accepted
2024-08-08 17:51:38
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nktr-20240630.htm iXBRL | 10-Q | 2007158
2 | EX-10.1(6) | nktr-ex10_16.htm | EX-10.1(6) | 192161
3 | EX-31.1 | nktr-ex31_1.htm | EX-31.1 | 13480
4 | EX-31.2 | nktr-ex31_2.htm | EX-31.2 | 13690
5 | EX-32.1 | nktr-ex32_1.htm | EX-32.1 | 9358
| Complete submission text file | 0000950170-24-094231.txt |  | 7943774

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nktr-20240630.xsd | EX-101.SCH | 1013340
59 | EXTRACTED XBRL INSTANCE DOCUMENT | nktr-20240630_htm.xml | XML | 1423813

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24006 | Film No.: 241189850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)